PDCD1 and B-cell chronic lymphocytic leukemia: The SYK inhibitor entospletinib in combination with obinutuzumab downregulates the expression of PD-1 in CD4+ and CD8+ T-cell subsets of CLL patients, partially reversing the T-cell exhausted phenotype (98).